Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT

Background In REDUCE‐IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial), icosapent ethyl (IPE) versus placebo) reduced cardiovascular death, myocardial infarction, stroke, coronary revascularization, or unstable angina requiring hospitalization, but was associated with i...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Brian Olshansky, Deepak L. Bhatt, Michael Miller, Ph. Gabriel Steg, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Ralph T. Doyle, Rebecca A. Juliano, Lixia Jiao, Peter R. Kowey, James A. Reiffel, Jean‐Claude Tardif, Christie M. Ballantyne, Mina K. Chung
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Wiley 2023-03-01
Schriftenreihe:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Schlagworte:	atrial fibrillation bleeding eicosapentaenoic acid icosapent ethyl prevention
Online-Zugang:	https://www.ahajournals.org/doi/10.1161/JAHA.121.026756
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!